54 programming-"the"-"DAAD"-"UCL"-"U"-"SciLifeLab"-"IMPRS-ML"-"P"-"BioData"-"BioData" "Dr" positions at University of Manchester
Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
successful candidate will work with Professor Matt Sutton and Dr Rachel Meacock and other members of the NIHR ARC team and will be based in the Division of Population Health, Health Services Research and
-
leading Pension scheme Excellent employee health and wellbeing services including an Employee Assistance Programme Exceptional starting annual leave entitlement, plus bank holidays Additional paid closure
-
the guidance of Dr Mahetab Amer and in collaboration with academic and clinical partners in Manchester and across the UK; this will include working with clinical samples in accordance with governance procedures
-
Summary This is an outstanding opportunity for a Research Associate to work within the Leukaemia Stem Cell Niche (LSCN) group under the supervision of Dr Simona Valletta, based at both the Oglesby
-
essential for this role, as will experience of qualitative research methods. The postholder will work with Professor Paul Wilson, Dr Laura Sheard and other members of the NIHR ARC team and will be based in
-
an annual budget for the same. What you will get in return: Fantastic market leading Pension scheme Excellent employee health and wellbeing services including an Employee Assistance Programme Exceptional
-
employee health and wellbeing services including an Employee Assistance Programme Exceptional starting annual leave entitlement, plus bank holidays Additional paid closure over the Christmas period Local and
-
Programme Exceptional starting annual leave entitlement, plus bank holidays Additional paid closure over the Christmas period Local and national discounts at a range of major retailers As an equal
-
The research teams led by Dr Elena Bichenkova and Dr Costas Demonacos within the Faculty of Biology, Medicine and Health at the University of Manchester wish to appoint an enthusiastic and motivated
-
myelomonocytic leukaemia (CMML) is a blood cancer with few therapeutic options and dismal prognosis. Dr. Daniel Wiseman led a Phase 2 clinical trial (“AMMO”), testing the second-generation, orally-bioavailable